Sort
21,281 grants matching “influenza”
Megakaryocyte regulation by the gut microbiome
$651,165Melody Y Zeng · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · HL
The Movement of Influenza Virus In Human Population
$651,037Katherine A Poehling · Wake Forest University Health Sciences · R01 · FY2009 · AI
Inflammation and Therapy for Respiratory Virus Infection
$651,036Helene Rosenberg · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
PROJECT 2: Determine clinically relevant host-viral dependency networks for respiratory infections including SARS-CoV-2
$651,020Melanie Maria Ott · University Of California, San Francisco · U19 · FY2025 · AI
Forecasting tipping points in emerging and re-emerging infectious diseases
$650,877John M Drake · University Of Georgia · U01 · FY2014 · GM
Vanderbilt Vaccine and Treatment Evaluation Unit
$650,727Clarence Buddy Creech · Vanderbilt University Medical Center · UM1 · FY2023 · AI
Neutralization Fingerprinting Analysis of Polyclonal Antibody Responses against HIV-1
$650,713Ivelin Georgiev · Vanderbilt University Medical Center · R01 · FY2017 · AI
Boston Area Travel Medicine Network (BATMN)
$650,626Elizabeth Barnett · Boston Medical Center · U19 · FY2008 · CI
Adenovirus Protease Regulation and Antiviral Development
$650,457Brookhaven Science Assoc-Brookhaven Lab · R01 · FY2002 · AI
Inflammation and Therapy for Respiratory Virus Infection
$650,338Helene Rosenberg · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Eosinophils, Inflammation and Immunity
$650,338Helene Rosenberg · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions
$650,010Maria Yazdanbakhsh · Leiden University Medical Center · U01 · FY2022 · AI
Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions
$650,010Maria Yazdanbakhsh · Leiden University Medical Center · U01 · FY2024 · AI
Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions
$650,010Maria Yazdanbakhsh · Leiden University Medical Center · U01 · FY2025 · AI
Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions
$650,010Maria Yazdanbakhsh · Leiden University Medical Center · U01 · FY2023 · AI
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** INFECTIOUS DISEASES REMAIN A SIGNIFICANT THREAT TO ANIMAL WELFARE AND CONSUMER COST; THUS, DEVELOPING EFFICIENT METHODS TO DIAGNOSE AND CHARACTERIZE THESE INFECTIOUS AGENTS IS IMPORTANT FOR CONTROL. IN POULTRY, IMPROVING DIAGNOSTIC ASSAYS FOR RNA VIRUSES, SUCH AS AVIAN REOVIRUS (ARV), AVIAN CORONAVIRUS (ACOV, CAUSATIVE AGENT OF INFECTIOUS BRONCHITIS; IB), AND AVIAN ASTROVIRUSES (AASTVS), IS A KEY AREA IDENTIFIED BY NATIONAL POULTRY PRODUCER GROUPS. THE DIFFICULTY IN DIAGNOSING AND MANAGING THESE VIRAL DISEASES RESULTS IN COSTS ESTIMATED IN THE BILLIONS OF DOLLARS PER YEAR. DEVELOPING DIAGNOSTIC TESTS THAT WORK ON ALL GENETIC VARIANTS OF THESE VIRUSES, AND THAT CAN IDENTIFY WHICH GENETIC VARIANT IS PRESENT WILL INCREASE PRODUCTION EFFICIENCY AND IMPROVE ANIMAL WELFARE. WE HYPOTHESIZE THAT NEW SEQUENCING TECHNOLOGY WILL PROVIDE A MORE PRECISE DIAGNOSTIC ASSAY, WHILE MAINTAINING TIMELINESS AND AFFORDABILITY. FIRST, WE WILL DETERMINE THE FEASIBILITY OF USING THE NEWEST METHODS TO CREATE SEQUENCING LIBRARIES FOR ARV, ACOV, AND AASTV. SECOND, WE WILL TEST THIS TECHNIQUE USING DIAGNOSTIC SAMPLES OBTAINED FROM REAL-WORLD, VETERINARY DIAGNOSTIC LABS, USING SAMPLES KNOWN TO BE POSITIVE FOR ARV, ACOV, AND/OR AASTV. LASTLY, WE WILL DETERMINE IF THESE ASSAYS CAN BE MULTIPLEXED TO INCREASE THE EFFICIENCY OF THE ASSAYS EVEN FURTHER. OUR PROJECT WILL DEVELOP NEW DIAGNOSTIC ASSAYS FOR ARV, ACOV, AND AASTV. FURTHERMORE, THE KNOWLEDGE OBTAINED FROM THIS PROPOSAL CAN BE APPLIED TO OTHER INFECTIOUS DISEASES OF ANIMALS AND HUMANS, INCLUDING VIRUSES SUCH AS INFLUENZA VIRUSES, BACTERIA LIKE SALMONELLA, AND YET-TO-BE DISCOVERED AGENTS.
$650,000University Of Georgia Research Foundation, Inc. · · FY2023 · National Institute of Food and Agriculture
TRANSFORMATIVE PLATFORMS TO PREVENT AND CONTROL HIGHLY PATHOGENIC AVIAN INFLUENZA.
$650,000University Of Georgia Research Foundation, Inc. · · FY2025 · National Institute of Food and Agriculture
NOVEL VACCINE PLATFORMS FOR PREVENTION AND CONTROL OF INFLUENZA A H5N1 IN CATTLE
$650,000Cornell University · · FY2025 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** SWINE INFLUENZA CAUSED BY INFLUENZA A VIRUSES (IAVS) IS AN IMPORTANT RESPIRATORY DISEASE THAT CAUSES SIGNIFICANT ECONOMIC LOSSES FOR THE US SWINE INDUSTRY. ALTHOUGH SWINE INFLUENZA VACCINES HAVE BEEN WIDELY USED IN THE USA, SWINE INFLUENZA REMAINS INEFFECTIVELY CONTROLLED AND OUTBREAKS REMAIN A MAJOR AND GROWING PROBLEM FOR THE SWINE INDUSTRY. THE MAIN ISSUE IS THAT CURRENT SWINE VACCINES CANNOT KEEP UP WITH THE RAPID CHANGES OF CIRCULATING VIRUS STRAINS. THIS OFTEN LEADS TO VACCINES PROVIDING INEFFECTIVE CROSS-PROTECTION AGAINST DIFFERENT IAV STRAINS SUCH AS ANTIGENICALLY HETEROLOGOUS AND HETEROSUBTYPIC VIRUS STRAINS. COMMERCIALLY AVAILABLE SWINE LIVE ATTENUATED VACCINES (LAIVS) FROM BOEHRINGER INGELHEIM ANIMAL HEALTH OVERCOMES THE DISADVANTAGES OF TRADITIONAL KILLED VACCINES, BUT REASSORTS WITH CIRCULATING SWINE INFLUENZA VIRUSES. THIS HAS THE POTENTIAL TO GENERATE VIRULENT VIRUSES THAT COULD POSE A SIGNIFICANT THREAT TO ANIMAL AND HUMAN HEALTH. BECAUSE OF THE ISSUES WITH THE CURRENTLY AVAILABLE KILLED AND LIVE SWINE INFLUENZA VACCINE, THERE IS A CRITICAL NEED FOR SAFER AND EFFECTIVE SWINE INFLUENZA VACCINES.THE GOAL OF THIS PROJECT IS TO DEVELOP SAFE AND EFFECTIVE LIVE ATTENUATED SWINE INFLUENZA VACCINES USING NEWCASTLE DISEASE VIRUS (NDV) AS THE VECTOR. THIS APPROACH HAS POTENTIAL TO DEVELOP SAFER AND MORE EFFECTIVE SWINE INFLUENZA VACCINE. RECENTLY, WE SHOWED THAT NDV-BASED SWINE INFLUENZA VACCINE CAN PROVIDE COMPLETE PROTECTION IN PIGS AGAINST A HOMOLOGOUS SWINE INFLUENZA VIRUS CHALLENGE, INDICATING THE NDV-BASED VACCINE CAN BE USED IN PIGS. THEREFORE, WE HYPOTHESIZE THAT NDV-BASED SWINE INFLUENZA VACCINE CAN BE DEVELOPED AND HAS POTENTIAL TO PROVIDE CROSS-PROTECTION AGAINST DIFFERENT GENOTYPE AND SUBTYPE SIVS. ACCORDINGLY, OUR APPLICATION OFFERS A NOVEL STRATEGY TO PRODUCE SAFE AND EFFECTIVE SWINE INFLUENZA VACCINE USING THE NDV AS THE VECTOR. IF SUCCESSFUL, OUR STRATEGY HAS THE POTENTIAL TO REDUCE BOTH ANIMAL AND HUMAN INFLUENZA INFECTIONS, AND BLOCK POTENTIAL ZOONOTIC TRANSMISSION FROM SWINE TO HUMANS.DEVELOPMENT OF UNIVERSAL HUMAN AND SWINE INFLUENZA VACCINES IS IDEAL TO PROTECT PUBLIC AND ANIMAL HEALTH. HOWEVER, NO UNIVERSAL INFLUENZA VACCINE APPROACH HAS BEEN DEMONSTRATED TO BE FEASIBLE SO FAR. SUCCESSFUL COMPLETION OF THE TASKS IN THIS APPLICATION WILL OFFER AN ALTERNATIVE STRATEGY TO DEVELOP SAFE AND EFFECTIVE LIVE SWINE INFLUENZA VACCINE. FURTHERMORE, IT WILL PROVIDE IMPORTANT INSIGHT INTO HOW TO DEVELOP UNIVERSAL INFLUENZA VACCINES. SPECIFICALLY, PIGS HAVE BEEN DESCRIBED AS AN EXCELLENT MODEL FOR HUMAN INFLUENZA INFECTIONS BECAUSE SWINE HAVE CLINICAL MANIFESTATIONS AND PATHOGENESIS THAT IS HIGHLY SIMILAR TO THAT OF HUMAN INFECTIONS. THEREFORE, RESULTS OF THIS STUDY COULD PROVIDE INVALUABLE INSIGHTS INTO FUTURE VACCINATION STRATEGIES FOR HUMAN INFLUENZA VACCINES.
$650,000University Of Missouri System · · FY2024 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AVIAN INFLUENZA POSES A SERIOUS THREAT TO GLOBAL POULTRY HEALTH AND FOOD SECURITY. CURRENT VACCINES AGAINST THE PREVALENT H9N2 SUBTYPE ARE INADEQUATE, NECESSITATING INNOVATIVE APPROACHES. OUR RESEARCH AIMS TO DEVELOP EFFECTIVE MASS VACCINATION STRATEGIES USING MODIFIED LIVE ATTENUATED VACCINES (MLVS).THIS PROJECT WILL ANALYZE THE GENETIC MAKEUP OF THE H9N2 VIRUS TO UNDERSTAND ITS EVOLUTION AND IDENTIFY KEY TARGETS FOR VACCINE DEVELOPMENT. WE WILL CREATE AND TEST IMPROVED MLVS, ENSURING THEIR SAFETY AND EFFECTIVENESS IN PREVENTING DISEASE TRANSMISSION. ADDITIONALLY, WE WILL EXAMINE HOW THESE MLVS STIMULATE THE IMMUNE SYSTEM COMPARED TO TRADITIONAL VACCINES, FOCUSING ON MUCOSAL, HUMORAL, AND CELLULAR RESPONSES.OUR FINDINGS WILL SIGNIFICANTLY ENHANCE OUR UNDERSTANDING OF THE H9N2 VIRUS AND PROVIDE VALUABLE TOOLS FOR RAPIDLY ASSESSING NEW STRAINS. THIS KNOWLEDGE WILL DIRECTLY CONTRIBUTE TO THE DEVELOPMENT OF MORE EFFECTIVE VACCINES AGAINST AVIAN INFLUENZA, NOT ONLY USING MLVS BUT ALSO OTHER VACCINE TECHNOLOGIES.THIS INNOVATIVE APPROACH IS A DEPARTURE FROM TRADITIONAL METHODS AND COULD REVOLUTIONIZE POULTRY VACCINATION. THE POTENTIAL BENEFITS EXTEND BEYOND AVIAN INFLUENZA, PAVING THE WAY FOR SIMILAR STUDIES ON OTHER RESPIRATORY VIRUSES AFFECTING POULTRY AND LIVESTOCK. BY ADDRESSING THE LIMITATIONS OF CURRENT VACCINES AND DEVELOPING SAFER, MORE EFFECTIVE ALTERNATIVES,WE CAN PROTECT ANIMAL HEALTH, SAFEGUARD THE FOOD SUPPLY, AND MITIGATE THE ECONOMIC IMPACT OF AVIAN INFLUENZA OUTBREAKS.
$650,000University Of Georgia Research Foundation, Inc. · · FY2024 · National Institute of Food and Agriculture
Epidemiology, Prevention and Treatment of Influenza and Other Respiratory Infecti
$650,000William Kwabena Ampofo · Noguchi Memorial Institute / Medical Res · U01 · FY2013 · IP
EVALUATION OF A NOVEL SWINE INFLUENZA NANOVACCINE
$649,999Ohio State University, The · · FY2025 · National Institute of Food and Agriculture
THIS PROJECT SEEKS TO ANSWER A CRITICAL QUESTION: HOW DO BIRD FLU VIRUSES LIKE H5N1 ADAPT TO INFECT CATTLE, AND WHAT CAN BE DONE TO MITIGATE THE RISK? BIRD FLU VIRUSES, ONCE THOUGHT ONLY TO AFFECT BIRDS, ARE EVOLVING, AND H5N1 INFECTIONS HAVE RECENTLY EMERGED IN DAIRY COWS. WHILE NOT FATAL, THE INFECTION CAUSES LOSS OF APPETITE, NASAL DISCHARGE, REDUCED MILK PRODUCTION, AND VIRUS SHEDDING IN MILK, LEADING TO ECONOMIC LOSSES FOR FARMERS AND RAISING CONCERNS ABOUT FOOD SAFETY AND SECURITY. SINCE THE FIRST REPORTED CASE IN MARCH 2024, INFECTIONS IN DAIRY CATTLE HAVE CONTINUED TO RISE.TO BETTER UNDERSTAND AND PREVENT FUTURE OUTBREAKS, THIS PROJECT WILL EXAMINE HOW CERTAIN BIRD FLU STRAINS, PARTICULARLY H5, H7, AND H9, ADAPT TO INFECT CATTLE. INFLUENZA VIRUSES RELY ON SPECIFIC RECEPTORS ON HOST CELLS TO ENTER AND INITIATE INFECTION. WHILE SIALIC ACID (SA) MOLECULES ARE THE PRIMARY RECEPTORS, RECENT STUDIES SUGGEST THAT IMMUNE SYSTEM MOLECULES LIKE MHC CLASS-II MAY ALSO ACT AS ALTERNATIVE ENTRY POINTS. THIS RESEARCH WILL INVESTIGATE HOW THESE VIRUSES BIND TO VARIOUS CATTLE TISSUES, INCLUDING THE LUNGS, DIGESTIVE SYSTEM, AND MAMMARY GLANDS, TO ASSESS THEIR POTENTIAL RISK TO LIVESTOCK.ADDITIONALLY, WE WILL ANALYZE GENETIC CHANGES IN THE HEMAGGLUTININ (HA) PROTEIN, WHICH ENABLES THE VIRUS TO ATTACH TO HOST CELLS. UNDERSTANDING HOW THESE MUTATIONS AFFECT THE VIRUS'S ABILITY TO INFECT CATTLE COULD REVEAL THE RISK OF SPREADING BEYOND THE MAMMARY GLAND. TO ENSURE SAFETY AND ACCURACY, THESE EXPERIMENTS WILL BE CONDUCTED USING A SAFE, NON-INFECTIOUS PSEUDOVIRUS SYSTEM AND TISSUES COLLECTED POST-SLAUGHTER.BEYOND ANSWERING THESE SCIENTIFIC QUESTIONS, THIS PROJECT WILL DEVELOP A RISK ASSESSMENT TO GUIDE BETTER MITIGATION AND PREPAREDNESS STRATEGIES FOR PROTECTING CATTLE FROM EMERGING BIRD FLU STRAINS. THE FINDINGS WILL EVALUATE THE LIKELIHOOD OF VIRAL SPREAD, PROVIDE INSIGHTS INTO VIRAL EVOLUTION, AND INFORM VACCINE DEVELOPMENT TO SAFEGUARD LIVESTOCK. BY PROACTIVELY STUDYING HOW BIRD FLU SPREADS IN CATTLE, THIS RESEARCH WILL HELP PROTECT ANIMAL HEALTH, STRENGTHEN FOOD SECURITY, AND ENSURE THE RESILIENCE OF THE U.S. DAIRY AND BEEF INDUSTRIES.
$649,992University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2025 · National Institute of Food and Agriculture
Influenza Viral Genomics and Evolution
$649,966Jeffery Taubenberger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Analysis of Historical Influenza Viruses
$649,966Jeffery Taubenberger · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI